BeOne Medicines AG announces annual shareholder meeting

• BeOne Medicines schedules annual general meeting in Zürich, Switzerland on June 11, 2026.
• Shareholders to vote on 2025 audited standalone and consolidated financial statements, loss appropriation, liability discharge for board and executive management.
• Ballot includes board refresh items, including director elections plus re-election of chair, compensation committee members, independent voting representative, auditors, auditor pay authorization.
• Meeting also seeks advisory votes on 2025 executive compensation, Swiss statutory compensation report, non-financial matters report.
• Other proposals cover amendments to equity plans, share issuance mandate up to 20%, share repurchase mandate up to 10%, authorization to allocate shares to Amgen to maintain ownership percentage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12129982), on April 28, 2026, and is solely responsible for the information contained therein.